Details of Drug

Drug General Information (ID: D0264)
Drug Name	Carmustine
Drug Type	Small molecule
Drug Synonymous	Carmustine; carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; BCNU; Injectable carmustine, Direct Therapeutics Click to Show/Hide
Disease Class	2C12: Liver cancer; 2A00: Brain cancer
Therapeutic Class	Alkylating Agents
Structure
Structure	3D Structure		2D Structure
Formula	C5H9Cl2N3O2
InChI	1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)
InChIKey	DLGOEMSEDOSKAD-UHFFFAOYSA-N
Canonical SMILES	C(CCl)NC(=O)N(CCCl)N=O
External Link
	Pubchem ID	2578
	CAS Number	154-93-8
	CHEBI ID	3423
	TTD ID	D01OXI
	INTEDE ID	DR0278

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM003 Affected organization distribution AM004 Affected intra/extra-hepatic metabolism AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM006 Altered intestinal mucosa BM013 Competitive binding of plasma proteins BM017 CYP450 enzyme inhibition BM043 Additive immunosuppressive effects BM044 Additive myelosuppressive effects BM047 Additive thrombogenic effects BM054 Increased risk of GI mucosal injury/bleeding risk BM055 Increased risk of hepatotoxicity BM100 Antagonize the effect of vaccine/toxoid BM105 Antagonize the effect of probiotics BM106 Diminish the response to diagnostic skin test antigens BM107 Attenuated pharmacological effects (Unspecific)
Relation Graph

Full list of drugs interacting with Carmustine
Affected gastrointestinal absorption
	Altered intestinal mucosa					Drug Num: 15
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0491		Digoxin	C41H64O14	2724385	Moderate		Inter Info	[88], [89], [90], [91], [92]
D0340		Cinoxacin	C12H10N2O5	2762	Minor		Inter Info	[138]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Minor		Inter Info	[138]
D0438		Delafloxacin	C18H12ClF3N4O4	487101	Minor		Inter Info	[138]
D0573		Enoxacin	C15H17FN4O3	3229	Minor		Inter Info	[138]
D0712		Gatifloxacin	C19H22FN3O4	5379	Minor		Inter Info	[138]
D0716		Gemifloxacin	C18H20FN5O4	9571107	Minor		Inter Info	[138]
D0740		Grepafloxacin	C19H22FN3O3	72474	Minor		Inter Info	[138]
D0919		Levofloxacin	C18H20FN3O4	149096	Minor		Inter Info	[138]
D0943		Lomefloxacin	C17H19F2N3O3	3948	Minor		Inter Info	[138]
D1155		Norfloxacin	C16H18FN3O3	4539	Minor		Inter Info	[138]
D1165		Ofloxacin	C18H20FN3O4	4583	Minor		Inter Info	[138]
D1499		Sparfloxacin	C19H22F2N4O3	60464	Minor		Inter Info	[138]
D1657		Trovafloxacin	C20H15F3N4O3	62959	Minor		Inter Info	[138]
D1092		Moxifloxacin	C21H24FN3O4	152946	Minor		Inter Info	[138]
Affected organization distribution
	Competitive binding of plasma proteins					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1244		Penbutolol	C18H29NO2	37464	Minor		Inter Info	[139]
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0344		Cisplatin	Cl2H6N2Pt	5702198	Moderate		Inter Info	[84], [85]
D0400		Cyclophosphamide	C7H15Cl2N2O2P	2907	Moderate		Inter Info	[84], [85]
Pharmacodynamic additive effects
	Additive immunosuppressive effects					Drug Num: 71
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0023		Adalimumab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0146		Baricitinib	C16H17N7O2S	44205240	Major		Inter Info	[10], [11], [12]
D0304		Certolizumab pegol	NA	NA	Major		Inter Info	[1], [5], [6]
D0661		Fingolimod	C19H33NO2	107970	Major		Inter Info	[20]
D0736		Golimumab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D1211		Ozanimod	C23H24N4O3	52938427	Major		Inter Info	[11], [25]
D1474		Siponimod	C29H35F3N2O3	44599207	Major		Inter Info	[10], [28]
D1575		Thiotepa	C6H12N3PS	5453	Major		Inter Info	[48]
D1600		Tofacitinib	C16H20N6O	9926791	Major		Inter Info	[49]
D1666		Upadacitinib	C17H19F3N6O	58557659	Major		Inter Info	[50]
D0348		Cladribine	C10H12ClN5O3	20279	Major		Inter Info	[11], [51]
D0614		Etanercept	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D0802		Infliximab	NA	NA	Major		Inter Info	[1], [2], [3], [4], [5], [6]
D1111		Natalizumab	NA	NA	Major		Inter Info	[52]
D0030		Aldesleukin	NA	NA	Moderate		Inter Info	[11], [53], [54]
D0032		Alefacept	NA	NA	Moderate		Inter Info	[29], [55], [56]
D0033		Alemtuzumab	NA	NA	Moderate		Inter Info	[57]
D0085		Anakinra	C20H23N5O7S2	146171046	Moderate		Inter Info	[58], [59], [60]
D0136		Azathioprine	C9H7N7O2S	2265	Moderate		Inter Info	[10], [11]
D0157		Bendamustine	C16H21Cl2N3O2	65628	Moderate		Inter Info	[11], [53], [54]
D0190		Bleomycin	C55H84N17O21S3+	5360373	Moderate		Inter Info	[11], [53], [54]
D0223		Busulfan	C6H14O6S2	2478	Moderate		Inter Info	[11], [53], [54]
D0246		Canakinumab	NA	NA	Moderate		Inter Info	[58], [59], [60]
D0260		Carboplatin	C6H12N2O4Pt	426756	Moderate		Inter Info	[11], [53], [54]
D0312		Chlorambucil	C14H19Cl2NO2	2708	Moderate		Inter Info	[11], [53], [54]
D0313		Chloramphenicol	C11H12Cl2N2O5	5959	Moderate		Inter Info	[10], [11], [83]
D0314		Chloramphenicol (ophthalmic)	C11H12Cl2N2O5	5959	Moderate		Inter Info	[10], [11], [83]
D0404		Cytarabine	C9H13N3O5	6253	Moderate		Inter Info	[11], [53], [54]
D0405		Cytarabine (liposomal)	C9H13N3O5	6253	Moderate		Inter Info	[11], [53], [54]
D0407		Dacarbazine	C6H10N6O	135398738	Moderate		Inter Info	[11], [53], [54]
D0429		Daunorubicin	C27H29NO10	30323	Moderate		Inter Info	[11], [53], [54]
D0430		Daunorubicin (liposomal)	C27H29NO10	30323	Moderate		Inter Info	[11], [53], [54]
D0443		Denosumab	NA	NA	Moderate		Inter Info	[87]
D0499		Dimethyl fumarate	C6H8O4	637568	Moderate		Inter Info	[93]
D0507		Diroximel fumarate	C11H13NO6	73330464	Moderate		Inter Info	[93]
D0627		Etoposide	C29H32O13	36462	Moderate		Inter Info	[11], [53], [54]
D0666		Floxuridine	C9H11FN2O5	5790	Moderate		Inter Info	[11], [53], [54]
D0675		Fluorouracil	C4H3FN2O2	3385	Moderate		Inter Info	[11], [53], [54]
D0780		Hydroxyurea	CH4N2O2	3657	Moderate		Inter Info	[11], [53], [54]
D0788		Idarubicin	C26H27NO9	42890	Moderate		Inter Info	[11], [53], [54]
D0790		Ifosfamide	C7H15Cl2N2O2P	3690	Moderate		Inter Info	[11], [53], [54]
D0793		Imatinib	C29H31N7O	5291	Moderate		Inter Info	[11], [53], [54]
D0851		Isatuximab	NA	NA	Moderate		Inter Info	[11], [53], [54]
D0945		Lomustine	C9H16ClN3O2	3950	Moderate		Inter Info	[11], [53], [54]
D0962		Lurbinectedin	C41H44N4O10S	57327016	Moderate		Inter Info	[11], [53], [54]
D0996		Melphalan	C13H18Cl2N2O2	460612	Moderate		Inter Info	[11], [53], [54]
D1007		Mercaptopurine	C5H4N4S	667490	Moderate		Inter Info	[11], [53], [54]
D1077		Mitomycin	C15H18N4O5	5746	Moderate		Inter Info	[11], [53], [54]
D1079		Mitoxantrone	C22H28N4O6	4212	Moderate		Inter Info	[11], [53], [54]
D1085		Monomethyl fumarate	C5H6O4	5369209	Moderate		Inter Info	[93]
D1113		Naxitamab	NA	NA	Moderate		Inter Info	[11], [53], [54]
D1140		Niraparib	C19H20N4O	24958200	Moderate		Inter Info	[102]
D1162		Ocrelizumab	NA	NA	Moderate		Inter Info	[103]
D1167		Olaparib	C24H23FN4O3	23725625	Moderate		Inter Info	[11], [104]
D1174		Omacetaxine mepesuccinate	C29H39NO9	285033	Moderate		Inter Info	[105]
D1193		Oxaliplatin	C8H14N2O4Pt	9887053	Moderate		Inter Info	[11], [53], [54]
D1375		Radium Ra 223 dichloride	NA	NA	Moderate		Inter Info	[117]
D1403		Rilonacept	NA	NA	Moderate		Inter Info	[58], [59], [60]
D1422		Roflumilast	C17H14Cl2F2N2O3	449193	Moderate		Inter Info	[11], [121]
D1487		Sodium phosphate, monobasic (p32)	NA	NA	Moderate		Inter Info	[122]
D1508		Streptozocin	C8H15N3O7	29327	Moderate		Inter Info	[11], [53], [54]
D1509		Strontium chloride Sr-89	Cl2Sr	5388879	Moderate		Inter Info	[10], [11], [123]
D1610		Topotecan	C23H23N3O5	60700	Moderate		Inter Info	[126]
D1671		Ustekinumab	NA	NA	Moderate		Inter Info	[128]
D1697		Vinblastine	C46H58N4O9	13342	Moderate		Inter Info	[11], [53], [54]
D1700		Vinorelbine	C45H54N4O8	5311497	Moderate		Inter Info	[11], [53], [54]
D1720		Zidovudine	C10H13N5O4	35370	Moderate		Inter Info	[10], [11], [129]
D0553		Efalizumab	NA	NA	Moderate		Inter Info	[130]
D0821		Interferon alfa-2a, Recombinant	NA	NA	Moderate		Inter Info	[11], [53], [54]
D0822		Interferon alfa-2b	C16H17Cl3I2N3NaO5S	71306834	Moderate		Inter Info	[11], [53], [54]
D1855		Palifermin	NA	NA	Moderate		Inter Info	[135]
	Additive myelosuppressive effects					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0337		Cimetidine	C10H16N6S	2756	Major		Inter Info	[13], [14], [15]
D0370		Clozapine	C18H19ClN4	135398737	Major		Inter Info	[11], [16], [17]
D0433		Deferiprone	C7H9NO2	2972	Major		Inter Info	[10], [18], [19]
D1443		Samarium (153Sm) lexidronam	Sm	23951	Major		Inter Info	[27]
D0710		Ganciclovir	C9H13N5O4	135398740	Moderate		Inter Info	[10], [11], [97], [98]
D1676		Valganciclovir	C14H22N6O5	135413535	Moderate		Inter Info	[10], [11], [97], [98]
	Additive thrombogenic effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1569		Thalidomide	C13H10N2O4	5426	Major		Inter Info	[32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47]
	Increased risk of GI mucosal injury/bleeding risk					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1102		Nalidixic acid	C12H12N2O3	4421	Major		Inter Info	[24]
	Increased risk of hepatotoxicity					Drug Num: 24
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0900		Leflunomide	C12H9F3N2O2	3899	Major		Inter Info	[21]
D0944		Lomitapide	C39H37F6N3O2	9853053	Major		Inter Info	[22]
D1073		Mipomersen	C230H324N67O122P19S19	118984467	Major		Inter Info	[23]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Major		Inter Info	[26]
D1556		Teriflunomide	C12H9F3N2O2	54684141	Major		Inter Info	[21]
D0114		Asparaginase Escherichia coli	NA	NA	Moderate		Inter Info	[61], [62], [63], [10], [11], [64], [65], [66], [67], [68], [69], [70], [71]
D0113		Asparaginase Erwinia chrysanthemi	NA	NA	Moderate		Inter Info	[61], [62], [63], [10], [11], [64], [65], [66], [67], [68], [69], [70], [71]
D0149		Bedaquiline	C32H31BrN2O2	5388906	Moderate		Inter Info	[74]
D0199		Brentuximab vedotin	NA	NA	Moderate		Inter Info	[78]
D0232		Calaspargase pegol	NA	NA	Moderate		Inter Info	[61], [62], [63], [10], [11], [64], [65], [66], [67], [68], [69], [70], [71]
D0248		Cannabidiol	C21H30O2	644019	Moderate		Inter Info	[11], [82]
D0357		Clofarabine	C10H11ClFN5O3	119182	Moderate		Inter Info	[86]
D0554		Efavirenz	C14H9ClF3NO2	64139	Moderate		Inter Info	[94], [95]
D0584		Epirubicin	C27H29NO11	41867	Moderate		Inter Info	[10], [11], [96]
D0789		Idelalisib	C22H18FN7O	11625818	Moderate		Inter Info	[99]
D1025		Methotrexate	C20H22N8O5	126941	Moderate		Inter Info	[11], [100]
D1106		Naltrexone	C20H23NO4	5360515	Moderate		Inter Info	[101]
D1239		Peginterferon beta-1a	NA	NA	Moderate		Inter Info	[106], [107], [108], [109]
D1389		Remdesivir	C27H35N6O8P	121304016	Moderate		Inter Info	[10], [11], [118], [119], [120]
D1589		Tioguanine	C5H5N5S	2723601	Moderate		Inter Info	[124], [125]
D1615		Trabectedin	C39H43N3O11S	108150	Moderate		Inter Info	[11], [127]
D0826		Interferon beta-1a	NA	NA	Moderate		Inter Info	[106], [107], [108], [109]
D0827		Interferon beta-1b	NA	NA	Moderate		Inter Info	[106], [107], [108], [109]
D1234		Pegaspargase	C14H19NO	436058	Moderate		Inter Info	[61], [62], [63], [10], [11], [64], [65], [66], [67], [68], [69], [70], [71]
Pharmacodynamic antagonistic effects
	Antagonize the effect of vaccine/toxoid					Drug Num: 23
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1744		Bacillus calmette-guerin substrain tice live antigen	NA	NA	Major		Inter Info	[7], [8], [9]
D1839		Measles virus vaccine live attenuated	NA	NA	Major		Inter Info	[7], [8], [9]
D1849		Mumps virus strain B level jeryl lynn live antigen	NA	NA	Major		Inter Info	[7], [8], [9]
D1881		Rotavirus vaccine	NA	NA	Major		Inter Info	[7], [8], [9]
D1882		Rubella virus vaccine	NA	NA	Major		Inter Info	[7], [8], [9]
D1890		Smallpox (Vaccinia) Vaccine, Live	NA	NA	Major		Inter Info	[29], [10], [30]
D1897		Talimogene laherparepvec	NA	NA	Major		Inter Info	[31]
D1914		Typhoid vaccine (live)	NA	NA	Major		Inter Info	[7], [8], [9]
D1920		Varicella Zoster Vaccine (Recombinant)	NA	NA	Major		Inter Info	[7], [8], [9]
D1922		Yellow Fever Vaccine	NA	NA	Major		Inter Info	[7], [8], [9]
D0089		Anthrax vaccine	NA	NA	Moderate		Inter Info	[29], [72], [73]
D0366		Clostridium tetani toxoid antigen (formaldehyde inactivated)	NA	NA	Moderate		Inter Info	[29], [72], [73]
D0755		Hepatitis A Vaccine	NA	NA	Moderate		Inter Info	[29], [72], [73]
D0756		Hepatitis B Vaccine (Recombinant)	NA	NA	Moderate		Inter Info	[29], [72], [73]
D0767		Human papillomavirus type 11 L1 capsid protein antigen	NA	NA	Moderate		Inter Info	[29], [72], [73]
D0803		Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)	NA	NA	Moderate		Inter Info	[29], [72], [73]
D0804		Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)	NA	NA	Moderate		Inter Info	[29], [72], [73]
D0999		Meningococcal polysaccharide vaccine group C	NA	NA	Moderate		Inter Info	[29], [72], [73]
D1259		Pfizer-BioNTech Covid-19 Vaccine	NA	NA	Moderate		Inter Info	[110], [29], [10], [111], [112], [113], [72], [114], [115], [116], [73]
D1307		Poliovirus type 1 antigen (formaldehyde inactivated)	NA	NA	Moderate		Inter Info	[29], [72], [73]
D1662		Typhoid vaccine (inactivated)	NA	NA	Moderate		Inter Info	[29], [72], [73]
D1692		Vibrio cholerae CVD 103-HgR strain live antigen	NA	NA	Moderate		Inter Info	[29], [72], [73]
D1838		Lyme disease vaccine (recombinant OspA)	NA	NA	Moderate		Inter Info	[134]
	Antagonize the effect of probiotics					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1749		Bifidobacterium longum infantis	NA	NA	Moderate		Inter Info	[75], [76], [77]
D1827		Lactobacillus acidophilus	NA	NA	Moderate		Inter Info	[75], [76], [77]
	Diminish the response to diagnostic skin test antigens					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1755		Candida albicans	C29H27N2O12P	118855431	Moderate		Inter Info	[79], [80], [81]
D1765		Coccidioides immitis spherule	NA	NA	Moderate		Inter Info	[79], [80], [81]
D1912		Trichophyton mentagrophytes	NA	NA	Moderate		Inter Info	[79], [80], [81]
D1913		Tuberculin purified protein derivative	NA	NA	Moderate		Inter Info	[79], [80], [81]
	Attenuated pharmacological effects (Unspecific)					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0659		Filgrastim	NA	NA	Moderate		Inter Info	[131], [132], [133]
D1235		Pegfilgrastim	C27H46N4O19	70683024	Moderate		Inter Info	[136], [137]
D1446		Sargramostim	NA	NA	Moderate		Inter Info	[131], [132], [133]

References
1	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
2	Product Information. Enbrel (etanercept). Wyeth-Ayerst Laboratories, Philadelphia, PA.
3	Product Information. Humira (adalimumab). Abbott Pharmaceutical, Abbott Park, IL.
4	Product Information. Remicade (infliximab). Centocor Inc, Malvern, PA.
5	Product Information. Simponi (golimumab). Centocor Inc, Malvern, PA.
6	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. ".
7	Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998).
8	Product Information. Attenuvax (measles virus vaccine, live, attenuated). Merck &amp Co, Inc, West Point, PA.
9	Product Information. YF-Vax (yellow fever vaccine). sanofi pasteur, Swiftwater, PA.
10	Cerner Multum, Inc. "Australian Product Information.".
11	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12	Product Information. Olumiant (baricitinib). Lilly, Eli and Company, Indianapolis, IN.
13	Volkin RL, Shadduck RK, Winkelstein A, Zeigler ZR, Selker RG "Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine." Arch Intern Med 142 (1982): 243-5.[PMID: 7059252]
14	Selker RG, Moore P, LoDolce D "Bone-marrow depression with cimetidine plus carmustine." N Engl J Med 299 (1978): 834.[PMID: 692572]
15	Product Information. BiCNU (carmustine). Bristol-Myers Squibb, Princeton, NJ.
16	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
17	Canadian Pharmacists Association "e-CPS."
18	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
19	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."
20	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
21	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
22	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
23	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
24	Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY.
25	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
26	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
27	Product Information. Quadramet (samarium sm 153 lexidronam) Berlex Laboratories, Richmond, CA.
28	Product Information. Mayzent (siponimod). Novartis Pharmaceuticals, East Hanover, NJ.
29	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
30	Product Information. Dryvax (smallpox vaccine). Wyeth-Ayerst Laboratories, Philadelphia, PA.
31	Product Information. Imlygic (talimogene laherparepvec). Amgen USA, Thousand Oaks, CA.
32	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
33	Bennett CL, Schumock GT, Desai AA, et al "Thalidomide-associated deep vein thrombosis and pulmonary embolism." Am J Med 113 (2002): 603-6. [PMID: 12459408]
34	Cavo M, Zamagni E, Cellini C, et al. "Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy." Blood 100 (2002): 2272-3. [PMID: 12229885]
35	Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A "Thalidomide and venous thrombosis." Ann Intern Med 136 (2002): 711. [PMID: 11992318]
36	Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
37	Fine HA, Wen PY, Maher EA, et al. "Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas." J Clin Oncol 21 (2003): 2299-304. [PMID: 12805330]
38	Lee CK, Barlogie B, Munshi N, et al "DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma." J Clin Oncol 21 (2003): 2732-9. [PMID: 12860952]
39	Osman K, Comenzo R, Rajkumar SV "Deep venous thrombosis and thalidomide therapy for multiple myeloma." N Engl J Med 344 (2001): 1951-2. [PMID: 11419443]
40	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
41	Rajkumar SV, Hayman S, Gertz MA, et al. "Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma." J Clin Oncol 20 (2002): 4319-23. [PMID: 12409330]
42	Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J "Thromboembolic events during treatment with thalidomide." Blood 99 (2002): 4247-8. [PMID: 12043695]
43	Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R "Thalidomide alone or with dexamethasone for previously untreated multiple myeloma." J Clin Oncol 21 (2003): 16-9. [PMID: 12506164]
44	Zangari M, Anaissie E, Barlogie B, et al "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy." Blood 98 (2001): 1614-5. [PMID: 11520815]
45	Zangari M, Barlogie B, Anaissie E, et al "Deep vein thrombosis in patients with mutiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation." Br J Haematol 126 (2004): 715-21. [PMID: 15327525]
46	Zangari M, Siegel E, Barlogie B, et al "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy." Blood 100 (2002): 1168-71. [PMID: 12149193]
47	Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM "A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma." Cancer 95 (2002): 1629-36. [PMID: 12365009]
48	Product Information. Thiotepa (thiotepa). Hikma USA (formerly West-Ward Pharmaceutical Corporation), Eatontown, NJ.
49	Product Information. Xeljanz (tofacitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50	Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
51	Product Information. Leustatin (cladribine). Ortho Biotech Inc, Raritan, NJ.
52	Product Information. Tysabri (natalizumab). Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.
53	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
54	Product Information. Fluorouracil injection (fluorouracil). Roche Laboratories, Nutley, NJ.
55	Product Information. Amevive (alefacept). Biogen, Cambridge, MA.
56	Product Information. Lonsurf (tipiracil-trifluridine). Taiho Oncology, Inc., Princeton, NJ.
57	Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
58	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
59	Product Information. Ilaris (canakinumab). Novartis Pharmaceuticals, East Hanover, NJ.
60	Product Information. Kineret (anakinra). Amgen, Thousand Oaks, CA.
61	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
62	Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
63	Cerner Multum, Inc "ANVISA Bulario Eletrnico.".
64	Christ TN, Stock W, Knoebel RW "Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen." J Oncol Pharm Pract 24 (2018): 299-308. [PMID: 28355969]
65	Jenkins R, Perlin E "Severe hepatotoxicity from Escherichia coli L-asparaginase." J Natl Med Assoc 79 (1987): 775-9. [PMID: 3305969]
66	Lu G, Karur V, Herrington JD, Walker MG "Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine" Proc (Bayl Univ Med Cent) 29 (2016): 46-7. [PMID: 26722167]
67	Product Information. Asparlas (calaspargase pegol). Servier, Boston, MA.
68	Product Information. Elspar (asparaginase). Merck & Co, Inc, West Point, PA.
69	Product Information. Erwinaze (asparaginase Erwinia chrysanthemi). EUSA Pharma, Newtown, PA.
70	Product Information. Oncaspar (pegaspargase). Rhone-Poulenc Rorer, Collegeville, PA.
71	Burke PW, Aldoss I, Lunning MA, et.al "High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles." Blood 122 (2013): 2671. [PMID: 29407583]
72	Product Information. Imovax Rabies (rabies vaccine). sanofi pasteur, Swiftwater, PA.
73	Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations.".
74	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
75	Borriello SP, Hammes WP, Holzapfel W, et.al "Safety of probiotics that contain lactobacilli or bifidobacteria." Clin Infect Dis 36 (2003): 775-80. [PMID: 12627362]
76	Schlegel L, Lemerle S, Geslin P "Lactobacillus species as opportunistic pathogens in immunocompromised patients." Eur J Clin Microbiol Infect Dis 17 (1998): 887-8. [PMID: 10052559]
77	Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis 35 (2002): 1155-60. [PMID: 12410474]
78	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
79	Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative). Connaught Laboratories Ltd, Toronto, ON.
80	Product Information. Candin (candida albicans extract). Nielsen Biosciences Inc, San Diego, CA.
81	Product Information. Spherulin (coccidioidin skin test). ALK Laboratories Inc, Wallingford, CT.
82	Product Information. Epidiolex (cannabidiol). Greenwich Biosciences Inc, Carlsbad, CA.
83	Sim SM, Back DJ, Breckenridge AM "The effect of various drugs on the glucuronidation of zidovudine (azidothymidine AZT) by human liver microsomes." Br J Clin Pharmacol 32 (1991): 17-21. [PMID: 1909542]
84	Fassas A, Gojo I, Rapoport A, et al. "Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy." Bone Marrow Transplant 28 (2001): 399-403. [PMID: 11571514]
85	Jones RB, Matthes S, Dufton C, et al "Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer." Breast Cancer Res Treat 26 (1993): S11-7. [PMID: 8400329]
86	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
87	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
88	Bjornsson TD, Huang AT, Roth P, Jacob DS, Christenson R "Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations." Clin Pharmacol Ther 39 (1986): 25-8. [PMID: 3943266]
89	Kuhlmann J, Wilke J, Rietbrock N "Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion." Clin Pharmacol Ther 32 (1982): 646-51. [PMID: 6897028]
90	Kuhlmann J, Zilly W, Wilke J "Effects of cytostatic drugs on plasma level and renal excretion of beta-acetyldigoxin." Clin Pharmacol Ther 30 (1981): 518-27. [PMID: 7285486]
91	Product Information. Lanoxicaps (digoxin). Glaxo Wellcome, Research Triangle Park, NC.
92	Rodin SM, Johnson BF "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet 15 (1988): 227-44. [PMID: 3056649]
93	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
94	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
95	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
96	Product Information. Ellence (epirubicin) Pharmacia and Upjohn, Kalamazoo, MI.
97	Product Information. Cytovene (ganciclovir). Genentech, South San Francisco, CA.
98	Product Information. Valcyte (valganciclovir) Roche Laboratories, Nutley, NJ.
99	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
100	Product Information. Methotrexate (methotrexate). Lederle Laboratories, Wayne, NJ.
101	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
102	Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
103	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
104	Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
105	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
106	Product Information. Avonex (interferon beta-1a). Biogen, Cambridge, MA.
107	Product Information. Betaseron (interferon beta-1b). Berlex, Richmond, CA.
108	Product Information. Plegridy (peginterferon beta-1a). Biogen Idec Inc, Cambridge, MA.
109	Product Information. Rebif (interferon beta-1a). Serono Laboratories Inc, Norwell, MA.
110	CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence." .
111	Product Information. Biothrax (anthrax vaccine adsorbed). Emergent BioSolutions Inc., Lansing, MI.
112	Product Information. Fluzone Influenza Vaccine (influenza virus vaccine). Connaught, Swiftwater, PA.
113	Product Information. Havrix (hepatitis A vaccine). SmithKline Beecham, Philadelphia, PA.
114	Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated). GlaxoSmithKline, Research Triangle Park, NC.
115	Product Information. Omnihib (haemophilus b conjugate vaccine). SmithKline Beecham, Philadelphia, PA.
116	CDC Centers for Disease Control and Prevention "Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.".
117	Product Information. Xofigo (radium Ra 223 dichloride). Bayer Pharmaceutical Inc, West Haven, CT.
118	European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
119	Gilead Sciences, Inc "About Remdesivir.".
120	US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM)".
121	Product Information. Daxas (roflumilast). Nycomed Inc, Princeton, NJ.
122	AnazaoHealth Corporation "P32 Sodium Phosphate."
123	Multum Information Services, Inc. Expert Review Panel.
124	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
125	Product Information. Tabloid (thioguanine). Prasco Laboratories, Cincinnati, OH.
126	Product Information. Hycamtin (topotecan). SmithKline Beecham, Philadelphia, PA.
127	Product Information. Yondelis (trabectedin). Janssen Pharmaceuticals, Titusville, NJ.
128	Product Information. Stelara (ustekinumab). Centocor Inc, Malvern, PA.
129	Product Information. Retrovir (zidovudine). Glaxo Wellcome, Research Triangle Park, NC.
130	Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.
131	Product Information. Granix (tbo-filgrastim). Teva Pharmaceuticals USA, North Wales, PA.
132	Product Information. Leukine (sargramostim). Immunex Corporation, Seattle, WA.
133	Product Information. Stemgen (ancestim) Amgen, Thousand Oaks, CA.
134	Shen AK, Mead PS, Beard CB. The Lyme disease vaccine--a public health perspective. Clin Infect Dis. 2011;52 Suppl 3:s247-s252. [PMID: 21217171]
135	Product Information. Kepivance (palifermin). Shire US Inc, Florence, KY.
136	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
137	Product Information. Neulasta (pegfilgrastim). Amgen, Thousand Oaks, CA.
138	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
139	Aguirre C, Rodriguez-Sasiain JM, Calvo R "Decrease in penbutolol protein binding as a consequence of treatment with some alkylating agents." Cancer Chemother Pharmacol 34 (1994): 86-8. [PMID: 8174208]

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence